繁體版 / 簡體版
 
NEWS ROOM
/ NEWS ROOM
2018-09-07
Fountain Biopharma Inc. Granted Taiwan Patent for Cancer stem cell culture platform

Fountain Biopharma Inc. announces a platform of in vitro co-culture system for cancer-associated fibroblasts and cancer cells was received patent from Taiwan Intellectual property office (TIPO).

Title of the patent is “CANCER-ASSOCIATED FIBROBLASTS IN MAINTAINING STEMNESS OF CANCER STEM CELLS”, patent No. I634209.

This platform is an in vitro co-culture system for cancer-associated fibroblasts (CAFs) and cancer cells for producing and maintaining cancer stem cells and uses thereof for screening drugs capable of inhibiting cancer stem cells. Also disclosed a paracrine signaling  for maintaining  cancer stemness could use to predict the drug response rate and prognosis in the cancer patients.

In the future, we could use this platform to discover the novel cancer stem cell markers, therapeutic targets and mechanism.


玩ag电子游戏被黑钱